---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-009225"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:16:30.409264+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atara Biotherapeutics cuts workforce by ~50%; expects $7.5M severance costs

## Summary
- Workforce reduction impacts ~50% of current employees; completion expected by June 2025.
- Estimated severance and related benefits of approximately $7.5 million, primarily one-time cash charges.
- Additional details to be disclosed in Q1 2025 Form 10-Q.
- Company may incur other charges not currently contemplated from the reduction.

## SEC filing metadata
- accession: 0000950170-25-009225
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/0000950170-25-009225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/atra-20250127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-009225
- JSON: https://secwatch.observer/filing/0000950170-25-009225.json
- Plain text: https://secwatch.observer/filing/0000950170-25-009225.txt

## Key facts
- Restructurings & Charges
  Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.5 million in total for severance and related benefits affecting workforce (approximately 50% of its current employees).
  - Type: restructuring
  - Charge: approximately $7.5 million in total for severance and related benefits
  - Affected area: workforce
  - Headcount: approximately 50% of its current employees
  source text: On January 27, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 50% of its current employees. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize approximately $7.5 million in total for severance and related benefits for employees laid off under the reduction in force.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/0000950170-25-009225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.